Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ-CP3B
- Development stage
- Preclinical
- Lead developer
- TJ Biopharma
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
**TJ-CP3B** is a novel tri-specific T cell engager developed by TJ Biopharma for cancer immunotherapy. It targets **CDCP1** (CUB domain-containing protein 1), a biomarker expressed on various solid tumors, while engaging **CD3** on T cells and incorporating conditional **4-1BB** activation. The 4-1BB component provides unique synergism by enabling intra-tumor T cell activation even with limited T cell infiltration, distinguishing it from conventional CD3 T cell engagers. It is designed for **CDCP1-positive solid tumors**.[1]
02
Targets
CDCP1 (CUB domain-containing protein 1)CD3 (T-cell surface glycoprotein CD3)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on TJ-CP3B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ-CP3B.